用19F MRI评估哮喘和慢性阻塞性肺疾病中的肺通气及支气管扩张剂反应
这项前瞻性双中心研究用吸入全氟丙烷的19F MRI评估哮喘、COPD和健康人的区域肺通气,并定量评价支气管扩张剂反应。COPD和哮喘患者的通气缺陷百分比均高于健康人,支气管扩张剂后哮喘降低33%、COPD降低14%。
要点
- 19F MRI可定量区域通气缺陷百分比(VDP),无需超极化示踪气体。
- COPD患者VDP几何均值27.2%、哮喘8.3%,均高于健康人1.8%。
- 支气管扩张剂后VDP哮喘降低33%、COPD降低14%,均P<.001。
核心结论
- 吸入全氟丙烷19F MRI对肺部疾病相关的区域通气改变敏感,并能定量评估支气管扩张剂治疗后的变化。
研究设计与样本
- 前瞻性双中心研究,纳入35例哮喘、21例COPD和38例健康参与者;采用吸入79%全氟丙烷与21%氧气混合气体的19F MRI,参考标准为常规肺功能检查。
关键影像表现/征象
- 19F MRI通过全氟丙烷分布计算通气缺陷百分比(VDP),反映区域通气异常。
- COPD患者VDP几何均值27.2%,哮喘患者8.3%,健康人1.8%。
诊断标准与关键数值
- VDP几何均值比:COPD vs 健康人15.2(95%CI:11.1,20.6),哮喘 vs 健康人4.6(95%CI:3.2,6.6),均P<.001。
- 支气管扩张剂后VDP哮喘从8.3%降至5.6%(降低33%),COPD从27.2%降至23.3%(降低14%),均P<.001。
临床应用与阅片要点
- 19F MRI可定量区域通气异质性,补充常规肺功能检查无法提供的空间信息。
- VDP可用于评估哮喘和COPD患者支气管扩张剂前后的区域通气变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Pulmonary function tests are central to diagnosis and monitoring of respiratory diseases but do not provide information on regional lung function heterogeneity. Fluorine 19 (19F) MRI of inhaled perfluoropropane permits quantitative and spatially localized assessment of pulmonary ventilation properties without tracer gas hyperpolarization. Purpose To assess regional lung ventilation properties using 19F MRI of inhaled perfluoropropane in participants with asthma, participants with chronic obstructive pulmonary disease (COPD), and healthy participants, including quantitative evaluation of bronchodilator response in participants with respiratory disease. Materials and Methods This prospective, dual-center study included participants with asthma or COPD from July 2019 to September 2022 and healthy participants from May 2018 to June 2019. Participants underwent conventional spirometry, proton MRI, and 19F MRI following inhalation of a 79% perfluoropropane and 21% oxygen gas mixture. Three-dimensional 19F MRI scans were acquired during a single breath hold. For participants with asthma or COPD, spirometric and MRI measurements were repeated following administration of nebulized salbutamol. Ventilation defect percentage (VDP) was calculated from perfluoropropane distribution. Linear mixed-effects models were used to assess differences in VDP between participant groups and before and after bronchodilator administration. Results Thirty-five participants with asthma (mean age, 50 years ± 18 [SD]; 21 male participants), 21 participants with COPD (mean age, 69 years ± 6; 14 male participants), and 38 healthy participants (mean age, 41 years ± 11; 20 male participants) were evaluated. 19F MRI-derived VDP was elevated in participants with COPD (geometric mean, 27.2%) and participants with asthma (geometric mean, 8.3%) compared with healthy participants (geometric mean, 1.8%; geometric mean ratio, 15.2 [95% CI: 11.1, 20.6] for COPD and 4.6 [95% CI: 3.2, 6.6] for asthma; P < .001 for both). After bronchodilator administration, VDP was reduced by 33% in participants with asthma (from 8.3% to 5.6%) and 14% in participants with COPD (from 27.2% to 23.3%; P < .001 for both). Conclusion 19F MRI of inhaled perfluoropropane was sensitive to changes in regional ventilation properties associated with lung disease and enabled quantification of changes following bronchodilator therapy. Published under a CC BY-NC-ND 4.0 license. Supplemental material is available for this article. See also the editorial by Unger in this issue.
引用
- Pippard BJ, Neal MA, Holland CW, et al. Assessing Lung Ventilation and Bronchodilator Response in Asthma and Chronic Obstructive Pulmonary Disease with 19F MRI. Radiology. 2024. PMID: 39718495. doi:10.1148/radiol.240949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。